Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda-Gay Edwards

Physician Assistant, Medical Washington, DC Physician Assistant

NPI 1841784691 CMS profile 10463761

2150 Pennsylvania Ave Nw, Ste 7, Washington, DC 20037

Open in the dashboard

General payments

$4,479

112 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda-Gay Edwards of Washington, DC is reported in the CMS Open Payments database as having received $4,479 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,541 38
2024 General $1,420 35
2023 General $666 6
2022 General $340 15
2021 General $512 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda-Gay Edwards
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amanda-Gay Edwards were reported at $1,541. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amanda-Gay Edwards Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $512 $156 $41–$563 $132
2022 $340 $185 $55–$649 $149
2023 $666 $199 $58–$717 $160
2024 $1,420 $206 $62–$740 $164
2025 $1,541 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,183 31 payments
  2. Boston Scientific Corporation $941 18 payments
  3. Abbott Laboratories $839 24 payments
  4. AbbVie, Inc. $614 25 payments
  5. Relievant Medsystems, Inc. $363 1 payment
  6. SPR Therapeutics, Inc $179 2 payments
  7. Vertos Medical, Inc. $154 2 payments
  8. Painteq LLC $61 1 payment
  9. Takeda Pharmaceuticals U.S.A., Inc. $24 1 payment
  10. Globus Medical, Inc. $21 1 payment
  11. Other $100 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,576 105 payments
  2. Travel and Lodging $858 6 payments
  3. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. Intracept Pain $970 11 payments
  2. SYNCHROMEDII $554 10 payments
  3. Intracept Pain $363 1 payment
  4. Intracept Pain $363 1 payment
  5. Intracept Pain $363 1 payment
  6. INCEPTIV $305 7 payments
  7. BOTOX $292 11 payments
  8. UBRELVY $283 11 payments
  9. INTELLIS ADAPTIVESTIM $275 13 payments
  10. ETERNA $237 3 payments
  11. Other $1,659 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,677

Median for Physician Assistant: 241

Drug cost

$49,800

Median for Physician Assistant: $4,110

Branded share of claims

15.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 112 $6,584
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 322 $6,491
Gabapentin Generic 439 $6,203
Pregabalin Generic 216 $4,080
Tizanidine Hcl Generic 130 $3,777
Oxycontin Oxycodone Hcl Brand 11 $3,018
Cyclobenzaprine Hcl Generic 361 $2,995
Duloxetine Hcl Generic 175 $2,919
Diclofenac Sodium Generic 68 $2,306
Oxycodone Hcl Generic 181 $2,265

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$32,905

Medicare's payments for the services billed

Medicare patients

88

Average age 64

Services billed

552

62 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 35%
Diabetes 33%
Chronic kidney disease 22%
COPD 20%
Ischemic heart disease 19%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record